Search results for "JUNCTION"

showing 10 items of 862 documents

Giant Dzyaloshinskii-Moriya Interaction and Room-Temperature Nanoscale Skyrmions in CoFeB/MgO Heterostructures

2021

Magnetic skyrmions in heavy metal (HM)/CoFeB/MgO structures are of particular interest for skyrmion-based magnetic tunnel junction (MTJ) devices because of their reliable generation, stability and read-out through purely electrical methods. To optimize the properties, such as stability, a strong Dzyaloshinskii-Moriya interaction (DMI) is required at room temperature. Here, using first-principles calculations, we demonstrate that giant DMI can be obtained in Ir/CoFe structures with an Fe-terminated configuration. Moreover, Brillouin light scattering measurements show that indeed Ta/Ir/Co20Fe60B20/MgO thin films with perpendicular magnetic anisotropy exhibit a large DMI value (1.13 mJ/m2), wh…

Brillouin zoneTunnel magnetoresistanceMaterials scienceCondensed matter physicsSkyrmionHeterojunctionThin filmMagnetic force microscopeNanoscopic scaleLight scatteringSSRN Electronic Journal
researchProduct

Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon

2007

Abstract It is well accepted that endogenous cannabinoids and CB1 receptors are involved in the regulation of smooth muscle contractility and intestinal motility, through a mechanism mainly related to reduction of acetylcholine release from cholinergic nerve endings. Because, few data exist on a possible modulatory action of the cannabinoid agents on the non-adrenergic non-cholinergic (NANC) excitatory and inhibitory neurotransmission, the aim of the present study was to investigate the effects of cannabinoid drugs on the NANC responses elicited by electrical field stimulation (EFS) in the circular muscle of mouse proximal colon. Colonic contractions were monitored as changes in endoluminal…

CB1 receptorIndolesCannabinoid receptormedicine.medical_treatmentSynaptic TransmissionSettore BIO/09 - FisiologiaEnteric Nervous SystemReceptor Cannabinoid CB2Micechemistry.chemical_compoundPiperidinesReceptor Cannabinoid CB1Fatty acid amide hydrolaseCannabinoid receptor type 2musculoskeletal neural and ocular physiologyAnandamideSmooth muscle contractionRimonabantAgonistmedicine.medical_specialtyColonPolyunsaturated Alkamidesmedicine.drug_classMorpholinesNeuromuscular JunctionArachidonic AcidsIn Vitro TechniquesNaphthalenesTachykininsInternal medicineCannabinoid Receptor ModulatorsIntestinal motilitymedicineAnimalsCannabinoidReceptors TachykininPharmacologyDose-Response Relationship DrugCannabinoidsExcitatory Postsynaptic PotentialsNANC relaxationURB597Electric StimulationBenzoxazinesMice Inbred C57BLEndocrinologyInhibitory Postsynaptic PotentialschemistryPyrazolesNANC contractionCannabinoidGastrointestinal MotilityEndocannabinoidsPharmacological Research
researchProduct

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma…

1997

Tumor-reactive CD4+ T cells have been isolated from tumor patients, and their specifity but not T-cell receptor (TCR) repertoire has been analyzed. Since we have described CD4+ sarcoma-reactive T-cell clones, we now sought to determine whether the TCR repertoire of these clones provides information on the spectrum of recognized sarcoma antigens. We analyzed the TCR beta (TCRB) chain repertoire of 19 CD4+ HLA-DR-restricted T-cell clones reactive with the autologous sarcoma cell line MZ-MES-1, with HLA-DR-matched tumor cell lines of different tissue origins and B-cell blasts. We identified 7 different clonotypes, which used a limited set of TCRBV and TCRBJ segments. Although the CDR3 of the d…

CD4-Positive T-LymphocytesCancer ResearchReceptors Antigen T-Cell alpha-betaLymphocyteBiologyPolymerase Chain ReactionInterferon-gammaImmune systemAntigenAntigens NeoplasmStomach NeoplasmsTumor Cells CulturedHLA-DRmedicineHumansMelanomaPan-T antigensT-cell receptorSarcomaHLA-DR AntigensT lymphocyteFetal BloodJunctional diversityClone Cellsmedicine.anatomical_structureOncologyImmunologyInternational Journal of Cancer
researchProduct

Quantum interference and the time-dependent radiation of nanojunctions

2021

Using the recently developed time-dependent Landauer-B\"uttiker formalism and Jefimenko's retarded solutions to the Maxwell equations, we show how to compute the time-dependent electromagnetic field produced by the charge and current densities in nanojunctions out of equilibrium. We then apply this formalism to a benzene ring junction, and show that geometry-dependent quantum interference effects can be used to control the magnetic field in the vicinity of the molecule. Then, treating the molecular junction as a quantum emitter, we demonstrate clear signatures of the local molecular geometry in the non-local radiated power.

CURRENTSElectromagnetic field116 Chemical sciencesFOS: Physical sciences02 engineering and technologyEffective radiated power114 Physical sciences01 natural sciencesCARBONELECTRONICSsymbols.namesake0103 physical sciencesMesoscale and Nanoscale Physics (cond-mat.mes-hall)OSCILLATIONSkvanttifysiikka010306 general physicsPHOTONICSPhysicsCondensed Matter - Mesoscale and Nanoscale Physicsnanoelektroniikkabusiness.industryBIOT-SAVARTsähkömagneettiset kentätCharge (physics)021001 nanoscience & nanotechnologyCondensed Matter::Mesoscopic Systems and Quantum Hall EffectTRANSPORT3. Good healthMagnetic fieldBiot–Savart lawMolecular geometryMaxwell's equationsQuantum electrodynamicsJUNCTIONsymbolsPhotonics0210 nano-technologybusiness
researchProduct

Maintenance of the intestinal tube in Caenorhabditis elegans: the role of the intermediate filament protein IFC-2.

2008

The Caenorhabditis elegans intestinal lumen is surrounded by a dense cytoplasmic network that is laterally attached to the junctional complex and is referred to as the endotube. It localizes to the terminal web region which anchors the microvillar actin filament bundles and is particularly rich in intermediate filaments. To examine their role in intestinal morphogenesis and function, C. elegans reporter strains were generated expressing intestine-specific CFP-tagged intermediate filament polypeptide IFB-2. When these animals were treated with dsRNA against intestinal intermediate filament polypeptide IFC-2, the endotube developed multiple bubble-shaped invaginations that protruded into the …

Cancer ResearchBiologyCell junctionProtein filamentTerminal webIntermediate Filament ProteinsMicroscopy Electron TransmissionIntermediate Filament ProteinAnimalsHomeostasisIntestinal MucosaIntermediate filamentCaenorhabditis elegansCaenorhabditis elegans ProteinsMolecular BiologyCaenorhabditis elegansEpithelial polarityMicroscopy ConfocalCell PolarityGene Expression Regulation DevelopmentalEpithelial CellsCell Biologybiology.organism_classificationCell biologyIntestinesCytoplasmDevelopmental BiologyDifferentiation; research in biological diversity
researchProduct

Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/met…

2021

TPS264 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care 1st-line therapy for advanced HER2+ GEJ/GC patients. M, an investigational Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher affinity for both 158V (high binding) and 158F (low binding) alleles of activating Fc receptor CD16A. Data suggest margetuximab coordinately enhances both innate and adaptive immunity, including antigen-specific T-cell responses to HER2. PD-1 and LAG-3 are T-cell checkpoint molecules that suppress T-cell function. Retifanlimab (also known as MGA012 or INCMGA00012) is a humanized, hinge-stabilized, IgG4 Κ anti-PD-1 mAb blocking binding of PD-L1 …

Cancer ResearchChemotherapybusiness.industrymedicine.drug_classMargetuximabmedicine.medical_treatmentAnti pd 1CancerMonoclonal antibodyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyTrastuzumabCancer researchMedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: II. Different types of lymphatic vessels.

1994

Abstract In diverse mammalian species, including (man, cow and rat) the very flat endothelial cells of lymphatic vessels of various organs, including the retothelial meshwork of sinus of lymph nodes, are connected by zonula -like plaque-bearing junctions which differ from the similarly structured junctions of blood vessel endothelia by the presence of desmoplakin or an as yet unknown but closely related plaque protein. These extended junctions, which also contain plakoglobin but none of the presently known desmogleins and desmocollins, are therefore different from the spot-like desmosomes ( maculae adhaerentes ) present in epithelia, myocardium and dendritic reticulum cells of lymphatic fol…

Cancer ResearchEndotheliumgovernment.form_of_governmentGuinea PigsPlakoglobinCell junctionAdherens junctionLymphatic SystemMicemedicineCell AdhesionAnimalsHumansMolecular BiologyDesmocollinsbiologyDesmoplakinCadherinCell BiologyAnatomyImmunohistochemistryCell biologyRatsLymphatic EndotheliumCytoskeletal ProteinsLymphatic systemmedicine.anatomical_structureIntercellular JunctionsDesmoplakinsMicroscopy Fluorescencebiology.proteingovernmentCattleEndothelium Vasculargamma CateninDesmogleinsCell Adhesion MoleculesDevelopmental BiologyDifferentiation; research in biological diversity
researchProduct

High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer.

2017

e15584 Background: Expression of the gastric mucosal tight junction protein, Claudin-18.2 (CLDN18.2), is altered in gastric cancer (GC). In a phase 2 clinical trial (NCT01630083; FAST), a monoclonal antibody against CLDN18.2 (IMAB362) significantly increased overall survival in European patients with CLDN18.2-positive (CLDN18.2+) gastric and gastroesophageal junction adenocarcinomas when added to an EOX chemotherapy regimen. As the GC occurrence is high in Japan, this study evaluated the prevalence of CLDN18.2 expression in Japanese patients with GC. Methods: CLDN18.2 expression was assessed in primary GC tumors and corresponding lymph node metastases (LNM) by cell membrane staining intens…

Cancer ResearchHigh prevalenceOncologyTight junctionbusiness.industryMonoclonalmedicineCancer researchPhases of clinical researchCancerClaudinmedicine.diseasebusinessJournal of Clinical Oncology
researchProduct

Mechanisms of tumor invasion: evidence from in vivo observations.

1985

The major mechanisms of tumor invasion in vivo are discussed in the present review. A special emphasis is placed on tumor dedifferentiation which has proved to be of paramount importance for the invasion process. Based on in vivo observations obtained from various human and animal tumors a concept for the mechanism of tumor invasion is proposed which mainly comprises the following basic events: the first and essential step in tumor invasion is the tumor dedifferentiation and dissociation at the invasion front. This apparently temporary and reversible process mobilizes the tumor cells out of the main tumor bulk and enables them to invade the host tissue by active locomotion. This mechanism i…

Cancer ResearchPathologymedicine.medical_specialtyCell divisionColonCellular differentiationBiologyHost tissueBasement MembraneExtracellular matrixIn vivoCell MovementmedicineAnimalsEdemaHumansNeoplasm InvasivenessProcess (anatomy)Cells CulturedDimethylhydrazinesCell DifferentiationMuscle SmoothCell biology12-DimethylhydrazineExtracellular MatrixNeoplasm ProteinsRatsOxygenInterstitial edemaIntercellular JunctionsOncologyColonic NeoplasmsAtrophyIntracellularCell DivisionPeptide HydrolasesCancer metastasis reviews
researchProduct

Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma : Updated r…

2019

16 Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant transformation, CLDN18.2 epitopes are exposed on the cell surface and accessible to targeted therapy. Zolbetuximab (formerly IMAB362) is a chimeric mAb that mediates specific killing of CLDN18.2+ cancer cells through immune effector mechanisms; single-agent activity has been reported in G/GEJ cancer. Methods: Patients (pts) with advanced HER2-negative (HER–) G/GEJ cancer with CLDN18.2 expression of ≥ 2+ staining intensity with the anti-CLDN18 43-14A mAb in ≥ 40% tumor cells were eligible (NCT01630083). Patients were randomized 1:1 to receive first-line EOX ± zolbetuxima…

Cancer ResearchTight junctionbusiness.industryCellMedizinmedicine.diseaseGastroesophageal JunctionEpitopeMalignant transformation03 medical and health sciences0302 clinical medicineFirst line therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchGastric mucosaMedicineAdenocarcinomabusiness030215 immunology
researchProduct